Organic revenue growth of 13% was primarily driven by new resident additions, increased script volumes, and a shift toward higher-acuity care.

Adjusted EBITDA margins expanded by 50 basis points despite absorbing new public company costs and integrating early-stage acquisitions.

The company successfully navigated a branded inhaler category headwind caused by the American Rescue Plan through disciplined operational execution.

Clinical value was reinforced by over 100,000 interventions and an insurance optimization program that saved residents an estimated $56,000,000.

Management attributes their competitive advantage to a local service model that reduces labor burdens for facility operators facing a 'silver tsunami' of aging residents.

Strategic investments in 'Guardian Hub' and 'Guardian Note' messaging systems have improved real-time visibility and workflow efficiency for facility partners.

The company maintains a disciplined capital allocation strategy, utilizing strong cash flow to fund four acquisitions and multiple greenfield startups without external financing.

The 2026 adjusted EBITDA guidance was raised to $120,000,000–$124,000,000, reflecting a low double-digit growth framework applied to a $110,000,000 exit run rate.

Revenue guidance of $1,400,000,000–$1,420,000,000 remains unchanged as the company accounts for new pricing dynamics mandated by the Inflation Reduction Act (IRA).

Management expects to fully offset the anticipated 2026 EBITDA impact from IRA policy changes through contract renegotiations and operational efficiencies.

The company is closely monitoring the new Medicare Transaction Facilitator clearinghouse to prevent potential disruptions to cash flow and customer service levels.

Long-term projections for 2027 include an estimated $65,000,000 revenue headwind from further drug negotiations, which management views as manageable within their existing growth framework.

Recent greenfield startups and acquisitions currently dampen overall margins by approximately 90 basis points as they progress toward full maturity.

A significant competitor's bankruptcy filing is being monitored for potential share gain or disciplined M&A opportunities.

Stock-based compensation is expected to step up to a quarterly run rate of approximately $3,000,000 following new annual LTIP grants issued in March 2026.

The company increased its cash balance by approximately $60,000,000 during the year, highlighting a high cash conversion rate of approximately 60%.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that while Q4 benefited from favorable payor dynamics and high acuity, they are only projecting 'durable' drivers into the 2026 base.

The $110,000,000 EBITDA run rate excludes non-recurring net positive PBM payor adjustments and assumes acuity remains at current levels.

Management is actively working to align gross margin dollars with activity levels, noting that 92% of prescriptions dispensed are generics.

Progress was made with several payors in 2025 to rebalance profit contributions ahead of IRA-related branded drug price changes.

Consolidation among ALF operators is viewed as an opportunity to demonstrate service reliability to new operating groups.

Guardian has maintained service continuity across all facilities during recent ownership transitions in their core market segment.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.